Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Epic Pharma, LLC
EIR
•Epic Pharma, LLC•February 1, 2019

Epic Pharma, LLC – FDA EIR, Feb 1, 2019

Record Details

An FDA inspection of Epic Pharma, LLC, a manufacturer of prescription and over-the-counter human drugs in Laurelton, NY, was conducted from January 22 to February 1, 2019. This comprehensive inspection, performed under the FY 2019 Tier C Drug cGMP workplan and relevant CPGMs, covered the company’s Quality, Materials, Facilities and Equipment, and Packaging and Labeling systems. The inspection also addressed a post-approval review for Oxycodone Hydrochloride Tablets.

The inspection concluded with the issuance of a six-item FDA 483, identifying significant deficiencies. These included the failure to validate manufacturing processes, inadequate examination and testing of in-process and finished product samples to ensure adherence to specifications (notably concerning low-fill Oxycodone HCl bottles), insufficient cleaning intervals for equipment, lack of detailed procedures for component handling, improper drug product storage conditions, and inadequate mechanical equipment calibration programs. Additionally, three verbal observations were discussed, highlighting overdue SOP reviews, absence of quality agreements with API suppliers, and a lack of data supporting blend and core tablet hold times.

A product recall (D-0297-2019) for Estradiol Tablets, initially Class III and reclassified to Class II, was also reviewed. The recall, due to a foreign tablet from a contract manufacturer, necessitated an expanded retail-level notification. Management acknowledged the observations and committed to providing a written response within 15 business days. The company's prior corrective actions from a 2017 inspection were deemed adequate. Follow-up on specific corrective actions and field alert reports is required for future inspections.

Company
Epic Pharma, LLC
Inspection date
February 1, 2019
Product type
Drugs
Office
New York District Office
People
  • Alice S. Tsao (Consumer Safety Officer at FDA)
  • Stephen G. Kurtis (recipient)
View Company Profile

ID · 1e895f54-a7eb-44c1-9cb2-14faf97f3237

Violation Codes10
21 CFR 211.68(a)21 CFR 211.110(a)21.U.S.C. 355(a)21 CFR 21121 CFR 211.67(a)21 CFR 820.10021 CFR 211.142(b)21 CFR 211.110(b)FD&C Act 505(a)21 CFR 211.80(a)

Full citation text and observation details available on the Dashboard.

Other documents for Epic Pharma, LLC
  • 483 - 2026-06-12June 12, 2026
  • 483 - 2023-10-23October 23, 2023
  • 483 - 2019-02-01February 1, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Epic Pharma, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.